Literature DB >> 29777584

Neuropsychiatric expression and catatonia in 22q11.2 deletion syndrome: An overview and case series.

Nancy J Butcher1,2, Erik Boot3,4, Anthony E Lang5,6, Danielle Andrade6,7, Jacob Vorstman8, Donna McDonald-McGinn2,9,10, Anne S Bassett1,3,11,12.   

Abstract

Individuals with 22q11.2 deletion syndrome (22q11.2DS) are at elevated risk of developing treatable psychiatric and neurological disorders, including anxiety disorders, schizophrenia, seizures, and movement disorders, often beginning in adolescence or early to mid-adulthood. Here, we provide an overview of neuropsychiatric features associated with 22q11.2DS in adulthood. Results of a new case series of 13 individuals with 22q11.2DS and catatonic features together with 5 previously reported cases support a potential association of this serious psychomotor phenotype with the 22q11.2 deletion. As in the general population, catatonic features in 22q11.2DS occurred in individuals with schizophrenia, other psychotic and non-psychotic psychiatric disorders, and neurological disorders like Parkinson's disease. We place the results in the context of an updated review of catatonia in other genetic conditions. The complex neuropsychiatric expression and risk profile of 22q11.2DS highlights the need to consider co-morbid factors and provide care tailored to the individual patient. The results reinforce the need for periodic monitoring for the emergence of psychiatric and neurological manifestations including catatonic features. Pending further research, enhanced recognition and informed anticipatory care promise to facilitate the early diagnosis that allows for timely implementation and optimization of effective treatments.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  22q11.2 deletion syndrome; DiGeorge syndrome; catatonia; neurological; neuropsychiatric; psychosis; schizophrenia

Mesh:

Year:  2018        PMID: 29777584      PMCID: PMC6209527          DOI: 10.1002/ajmg.a.38708

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  102 in total

1.  Basal ganglia calcification and psychosis in 22q11.2 deletion syndrome.

Authors:  M Sieberer; H Haltenhof; B Haubitz; B Pabst; K Miller; P Garlipp
Journal:  Eur Psychiatry       Date:  2005-06-20       Impact factor: 5.361

2.  22q11.2 deletion syndrome lowers seizure threshold in adult patients without epilepsy.

Authors:  Robert G Wither; Felippe Borlot; Alex MacDonald; Nancy J Butcher; Eva W C Chow; Anne S Bassett; Danielle M Andrade
Journal:  Epilepsia       Date:  2017-04-27       Impact factor: 5.864

3.  Missense mutations in the sodium-gated potassium channel gene KCNT1 cause severe autosomal dominant nocturnal frontal lobe epilepsy.

Authors:  Sarah E Heron; Katherine R Smith; Melanie Bahlo; Lino Nobili; Esther Kahana; Laura Licchetta; Karen L Oliver; Aziz Mazarib; Zaid Afawi; Amos Korczyn; Giuseppe Plazzi; Steven Petrou; Samuel F Berkovic; Ingrid E Scheffer; Leanne M Dibbens
Journal:  Nat Genet       Date:  2012-10-21       Impact factor: 38.330

4.  Response to clozapine in a clinically identifiable subtype of schizophrenia.

Authors:  Nancy J Butcher; Wai Lun Alan Fung; Laura Fitzpatrick; Alina Guna; Danielle M Andrade; Anthony E Lang; Eva W C Chow; Anne S Bassett
Journal:  Br J Psychiatry       Date:  2015-03-05       Impact factor: 9.319

5.  Catatonia and other motor syndromes in a chronically hospitalized psychiatric population.

Authors:  G Bush; G Petrides; A Francis
Journal:  Schizophr Res       Date:  1997-10-17       Impact factor: 4.939

6.  Clozapine: dangerous orphan or neglected friend?

Authors:  Saeed Farooq; Mark Taylor
Journal:  Br J Psychiatry       Date:  2011-04       Impact factor: 9.319

7.  Cognitive deficits associated with schizophrenia in velo-cardio-facial syndrome.

Authors:  Therese van Amelsvoort; Jayne Henry; Robin Morris; Michael Owen; Don Linszen; Kieran Murphy; Declan Murphy
Journal:  Schizophr Res       Date:  2004-10-01       Impact factor: 4.939

8.  Living with a child at risk for psychotic illness: the experience of parents coping with 22q11 deletion syndrome: an exploratory study.

Authors:  Laura Hercher; Georgette Bruenner
Journal:  Am J Med Genet A       Date:  2008-09-15       Impact factor: 2.802

9.  Psychosis and catatonia in fragile X: Case report and literature review.

Authors:  Tri Indah Winarni; Andrea Schneider; Neera Ghaziuddin; Andreea Seritan; Randi J Hagerman
Journal:  Intractable Rare Dis Res       Date:  2015-08

Review 10.  Endocrine disorders and the neurologic manifestations.

Authors:  Jeesuk Yu
Journal:  Ann Pediatr Endocrinol Metab       Date:  2014-12-31
View more
  6 in total

Review 1.  Neurological manifestation of 22q11.2 deletion syndrome.

Authors:  Michael Bayat; Allan Bayat
Journal:  Neurol Sci       Date:  2022-01-18       Impact factor: 3.307

2.  Possible Commonalities of Clinical Manifestations Between Dystonia and Catatonia.

Authors:  Kanako Ishizuka; Masako Tachibana; Toshiya Inada
Journal:  Front Psychiatry       Date:  2022-04-29       Impact factor: 4.157

Review 3.  Catatonia and the immune system: a review.

Authors:  Jonathan P Rogers; Thomas A Pollak; Graham Blackman; Anthony S David
Journal:  Lancet Psychiatry       Date:  2019-06-10       Impact factor: 77.056

4.  Psychiatric illness and regression in individuals with Phelan-McDermid syndrome.

Authors:  Teresa M Kohlenberg; M Pilar Trelles; Brittany McLarney; Catalina Betancur; Audrey Thurm; Alexander Kolevzon
Journal:  J Neurodev Disord       Date:  2020-02-12       Impact factor: 4.025

5.  A prospective descriptive study on prevalence of catatonia and correlates in an acute mental health unit in Nelson Mandela Bay, South Africa.

Authors:  Zukiswa Zingela; Louise Stroud; Johan Cronje; Max Fink; Stephan Van Wyk
Journal:  PLoS One       Date:  2022-03-08       Impact factor: 3.240

6.  CREB signaling activity correlates with differentiation and survival in medulloblastoma.

Authors:  Inna Armandari; Walderik W Zomerman; Sabine L A Plasschaert; Marlinde J Smit; Tosca E I Martini; Eduardo S de Camargo Magalhães; Shanna M Hogeling; Geesina C Rozema-Huizinga; Harm J Lourens; Tiny G J Meeuwsen-de Boer; Frank J G Scherpen; Eveline S J M de Bont; Sophia W M Bruggeman
Journal:  Sci Rep       Date:  2021-08-09       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.